The components of drug-linker conjugates for antibody drug conjugates (ADCs) are a cytotoxic drug that is active and a suitable linker. These conjugates can be used to create ADCs, which are highly selective and cytotoxic agents that are targeted for cancer cells after being joined to a monoclonal antibody.
The drug units in drug-linker conjugates are tubulin inhibitors and DNA damaging agents that have antitumor activity (i.e., ADC cytotoxins or payloads). Auristatins and Maytansinoids are the most widely used tubulin inhibitors, while Duocarmycins, Pyrrolobenzodiazepines, Camptothecines, and Daunorubicins/Doxorubicines are the most frequently used DNA damaging agents in ADCs. Additionally, a variety of conventional cytotoxic agents can be used in ADCs.
Cleavable and noncleavable ADC linkers are the two categories into which the majority of those currently undergoing clinical evaluation fall. Noncleavable linkers necessitate proteolytic degradation of the antibody component of the ADC in order to release the cytotoxic molecule, whereas cleavable linkers depend on cellular processes to release the toxin.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V88384 | MA-PEG4-VC-PAB-DMEA-duocarmycin DM TFA | MA-PEG4-VC-PAB-DMEA-duocarmycin DM TFA is a part of the antibody-coupled active molecule ADC (drug-linker conjugate for ADC), which is composed of the DNA minor groove alkylating agent Duocarmycin DM and the linker MA-PEG4-vc-PAB-DMEA. | |
|
V52111 | Mal-(CH2)5-Val-Cit-PAB-Eribulin | 2130869-21-3 | Mal-(CH2)5-Val-Cit-PAB-Eribulin is part of the antibody conjugate active molecule (drug-linker conjugate for ADC) and has anti-neoplastic activity. |
|
V54797 | Mal-amido-PEG8-Val-Ala-PAB-SG3200 | 2025353-40-4 | Mal-amido-PEG8-Val-Ala-PAB-SG3200 is a conjugate of antibody-active molecule conjugates (information disclosed in patent WO2016166300A1). |
|
V51217 | Mal-C2-Gly3-EDA-PNU-159682 | 2259318-53-9 | Mal-C2-Gly3-EDA-PNU-159682, a bioactive molecule-conjugate for ADC, consists of the ADC linker Mal-C2-Gly3-EDA and the potent ADC cytotoxic DMEA-PNU-159682. |
|
V51219 | Mal-C6-α-Amanitin | 1578249-76-9 | drug-linker conjugate for ADC |
|
V54788 | Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan | 2578019-72-2 | Mal-cyclohexane-Gly-Gly-Phe-Gly-Exatecan is a coupling compound that may be utilized in the synthesis/preparation of ADC. |
|
V52883 | MAL-di-EG-Val-Cit-PAB-MMAE | 2746391-62-6 | MAL-di-EG-Val-Cit-PAB-MMAE is a combination of the effective microtubule inhibitor Monomethyl Auristatin E (MMAE) and the peptide linker MAL-di-EG-Val-Cit-PAB. |
|
V76795 | MAL-di-EG-Val-Cit-PAB-MMAF | MAL-di-EG-Val-Cit-PAB-MMAF consists of an ADC linker (MAL-di-EG-Val-Cit-PAB) and a potent tubulin polymerization blocker (MMAF, Monomethyl auristatin F). | |
|
V105103 | Mal-GGFG-PAB-MMAE | 3055607-18-3 | Mal-GGFG-PAB-MMAE (compound 8) is a drug-linker complex composed of the mitotic inhibitor MMAE and the linker Mal-GGFG-PAB. |
|
V52908 | Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan | 1599439-54-9 | Mal-PEG2-Gly-Gly-Phe-Gly-Exatecan is an ADC drug-linker conjugate. |
|
V53302 | Mal-PEG4-VA-PBD | 1342820-68-1 | Mal-PEG4-VA-PBD is an antibody-conjugated active molecule, which is composed of the anti-tumor antibiotic Pyrrolobenzodiazepine (PBD) and Mal-PEG4-VA. |
|
V103258 | Mal-PEG4-Val-Cit-PAB-MMAE | Mal-PEG4-Val-Cit-PAB-MMAE is part of the ADC drug-linker conjugate. | |
|
V51214 | Mal-PEG4-VC-PAB-DMEA-PNU-159682 | 2259318-52-8 | drug-linker conjugate for ADC |
|
V54767 | Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA | 2259318-49-3 | Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is an antibody-conjugated active molecule, which is composed of the anti-tumor antibiotic Duocarmycin SA and Mal-PEG4-VC-PAB-DMEA-Seco. |
|
V53293 | Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan | 2495742-34-0 | Mal-PEG8-amide-Val-Ala-(4-NH2)-Exatecan is the conjugate used in the synthesis/preparation of ADC. |
|
V53107 | Mal-PEG8-Phe-Lys-PAB-Exatecan | 2679821-44-2 | Mal-PEG8-Phe-Lys-PAB-Exatecan (compound 15) is a part of the antibody conjugate active molecule ADC (drug-linker conjugate for ADC), consisting of a degradable linker Mal-PEG8-Phe-Lys-PAB and toxin consisting of the molecule Exatecan . |
|
V76792 | Mal-PEG8-Phe-Lys-PAB-Exatecan TFA | Mal-PEG8-Phe-Lys-PAB-Exatecan TFA is a bioactive molecule linker conjugate of antibody conjugated active molecule (ADC) (drug-linker conjugate for ADC), consisting of degradable linker Mal-PEG8-Phe- Lys-PAB is made up of the toxin molecule Exatecan. | |
|
V80671 | Mal-PEG8-Val-Ala-PAB-SB-743921 | Mal-PEG8-Val-Ala-PAB-SB-743921 (Compound D7) is an ADC drug-linker conjugate (Drug-Linker Conjugates for ADC). | |
|
V76790 | Mal-PEG8-Val-Cit-PAB-MMAF | Mal-PEG8-Val-Cit-PAB-MMAF is part of the antibody-linker conjugate for ADC. | |
|
V51216 | Mal-Phe-C4-VC-PAB-DMEA-PNU-159682 | 2259318-54-0 | drug-linker conjugate for ADC |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
